Moutih Rafei
Directeur Technique/Scientifique/R&D chez DEFENCE THERAPEUTICS INC.
Fortune : 57 400 $ au 31/05/2024
Postes actifs de Moutih Rafei
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| DEFENCE THERAPEUTICS INC. | Directeur/Membre du Conseil | 05/01/2021 | - |
| Directeur Technique/Scientifique/R&D | 09/10/2020 | - | |
| University of Montréal | Corporate Officer/Principal | - | - |
Historique de carrière de Moutih Rafei
Anciens postes connus de Moutih Rafei
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
IntelliStem Technologies, Inc.
 IntelliStem Technologies, Inc. BiotechnologyHealth Technology IntelliStem Technologies, Inc. is a Canadian biotechnology company that specializes in engineering stem cells for the development of next-generation cell therapy products. The private company is based in Toronto, Canada. The company's proprietary cell platforms, including Super Sentinel Cells (SSCs) for cancer therapeutics and IntelliCells for drug discovery and target identification, are genetically engineered. IntelliStem is currently moving into human clinical trials. The company was founded by Riam Shammaa, who has been the CEO since incorporation. | Directeur Technique/Scientifique/R&D | - | 01/08/2023 |
| Fondateur | - | 01/08/2023 |
Formation de Moutih Rafei
| McGill University | Doctorate Degree |
Statistiques
Internationale
| Canada | 5 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 2 |
| Founder | 2 |
| Director/Board Member | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| DEFENCE THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
IntelliStem Technologies, Inc.
IntelliStem Technologies, Inc. BiotechnologyHealth Technology IntelliStem Technologies, Inc. is a Canadian biotechnology company that specializes in engineering stem cells for the development of next-generation cell therapy products. The private company is based in Toronto, Canada. The company's proprietary cell platforms, including Super Sentinel Cells (SSCs) for cancer therapeutics and IntelliCells for drug discovery and target identification, are genetically engineered. IntelliStem is currently moving into human clinical trials. The company was founded by Riam Shammaa, who has been the CEO since incorporation. | Health Technology |
- Bourse
- Insiders
- Moutih Rafei
- Expérience
